Mouse and human urothelial cancer organoids: A tool for bladder cancer research

Author:

Mullenders Jasper,de Jongh Evelien,Brousali Anneta,Roosen Mieke,Blom Jan P. A.,Begthel Harry,Korving Jeroen,Jonges Trudy,Kranenburg Onno,Meijer Richard,Clevers Hans C.

Abstract

Bladder cancer is a common malignancy that has a relatively poor outcome. Lack of culture models for the bladder epithelium (urothelium) hampers the development of new therapeutics. Here we present a long-term culture system of the normal mouse urothelium and an efficient culture system of human bladder cancer cells. These so-called bladder (cancer) organoids consist of 3D structures of epithelial cells that recapitulate many aspects of the urothelium. Mouse bladder organoids can be cultured efficiently and genetically manipulated with ease, which was exemplified by creating genetic knockouts in the tumor suppressors Trp53 and Stag2. Human bladder cancer organoids can be derived efficiently from both resected tumors and biopsies and cultured and passaged for prolonged periods. We used this feature of human bladder organoids to create a living biobank consisting of bladder cancer organoids derived from 53 patients. Resulting organoids were characterized histologically and functionally. Organoid lines contained both basal and luminal bladder cancer subtypes based on immunohistochemistry and gene expression analysis. Common bladder cancer mutations like TP53 and FGFR3 were found in organoids in the biobank. Finally, we performed limited drug testing on organoids in the bladder cancer biobank.

Publisher

Proceedings of the National Academy of Sciences

Subject

Multidisciplinary

Reference63 articles.

1. Dutch Cancer Registry (NKR) (2018) Available at https://www.cijfersoverkanker.nl/. Accessed February 1, 2018.

2. Unlocking bladder cancer;Berdik;Nature,2017

3. Neoadjuvant treatment for muscle-invasive bladder cancer: The past, the present, and the future;Hermans;Urol Oncol,2018

4. Precision medicine for urothelial bladder cancer: Update on tumour genomics and immunotherapy;Felsenstein;Nat Rev Urol,2018

5. Immune checkpoint inhibitors in urothelial cancer: Recent updates and future outlook;Gopalakrishnan;Ther Clin Risk Manag,2018

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3